The popularity of weight-loss drugs like Ozempic has caught the attention of Galderma, a Swiss pharmaceutical company known for its skin care treatments. According to the CEO, the sunken-in look that can occur in some patients taking Ozempic presents an opportunity for their facial fillers products. Galderma has already started a study to evaluate the effects of Sculptra and Restylane for cheek augmentation and contour deficiencies in patients using GLP-1 treatments. Enrollment is ongoing, and results may be available by the end of the year.
The term “Ozempic face” has become increasingly common among dermatologists due to the widespread use of weight-loss medications. It refers to the sunken and aged appearance that can result from rapid weight loss. Galderma, which went public last month on the SIX Swiss Exchange, reported a 12.4% increase in sales year-over-year in the first quarter of the year. The company also owns popular drug store brand Cetaphil. The CEO remains optimistic about the growth potential in the fillers market and plans to capitalize on the trend of weight-loss drugs like Ozempic.
Galderma’s products like Sculptra are designed to restore the gaunt look associated with Ozempic face. The company believes that as more patients turn to weight-loss drugs, there will be an increase in demand for their facial fillers products. This is because fillers can help counteract some of the negative effects of rapid weight loss on facial features.
The study being conducted by Galderma aims to evaluate whether Sculptra and Restylane are effective at correcting cheek augmentation and contour deficiencies in patients using GLP-1 treatments like Ozempic. If successful, this could lead to increased demand for these products from both dermatologists and patients alike.
Overall, Galderma’s decision to capitalize on the trend of weight-loss drugs like Ozempic is strategic and well thought out. By offering products that address some of the negative side effects of rapid weight loss, they are positioning themselves as a leader in this growing market.
In conclusion, Galderma sees an opportunity in the “Ozempic face” phenomenon and believes that it could lead to an increase in demand for their facial fillers products. With their focus on research and innovation, they are well positioned to capitalize on this trend and continue their growth trajectory as a leading pharmaceutical company in Switzerland.